Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes.
Analytical ultracentrifugation (AUC) is a powerful tool for the study of particle size distributions and interactions with high accuracy and resolution. In this work, we show how the analysis of sedimentation velocity data from the AUC can be used to characterize nanocarrier drug delivery systems used in nanomedicine. Nanocarrier size distribution and the ratio of free versus nanoparticle-encapsulated drug in a commercially available liposomal doxorubicin formulation are determined using interference and absorbance based AUC measurements and compared with results generated with conventional techniques. Additionally, the potential of AUC in measuring particle density and the detection of nanocarrier sub-populations is discussed as well. The unique capability of AUC in providing reliable data for size and composition in a single measurement and without complex sample preparation makes this characterization technique a promising tool both in nanomedicine product development and quality control.
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy. Electronic address: dora.mehn@ec.europa.eu.
Dora
D
Mehn
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
Patrizia
P
Iavicoli
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
Noelia
N
Cabaleiro
SINTEF Materials and Chemistry, Department of Biotechnology and Nanomedicine, Sem Sælands v. 2A, N-7034 Trondheim, Norway.
Sven Even
SE
Borgos
University Grenoble Alpes, F38000 Grenoble, France; CEA, LETI, Minatec Campus, F38054 Grenoble, France.
Fanny
F
Caputo
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
Otmar
O
Geiss
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
Luigi
L
Calzolai
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
François
F
Rossi
Consumer Products Safety, Directorate General Joint Research Centre, European Commission, Directorate F - Health, Consumers and Reference Materials, Via E. Fermi, I-21027 Ispra (VA), Italy.
Douglas
D
Gilliland
D000903:Antibiotics, Antineoplastic / Q000032:analysis*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000032:analysis; D050997:Nanomedicine; D010316:Particle Size; D011092:Polyethylene Glycols / Q000032:analysis; D014461:Ultracentrifugation
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
AUC; Analytical ultracentrifugation; Doxorubicin hydrochloride (PubChem CID: 443939); Free drug; Liposome; Nanomedicine; Size distribution